Tag
A prospective study demonstrates that tumor-informed ctDNA-based minimal residual disease (MRD) testing significantly predicts recurrence and survival in HPV-independent HNSCC, offering a median five-month lead time over clinical detection
Researchers have identified DARS1 as a critical oncogenic driver in hepatocellular carcinoma. Beyond its role in protein synthesis, DARS1 enters the nucleus to modulate MYC signaling through the SAGA complex, offering a new therapeutic vuln
A multi-center study demonstrates that preoperative ctDNA detection significantly outperforms traditional clinical criteria in predicting nodal upstaging and survival outcomes for patients with clinical stage I/II ESCC, potentially redefini
This review evaluates the clinical utility of METER, a novel lp-WGBS workflow for ctDNA detection in RAS wild-type mCRC, demonstrating its prognostic value and cost-effectiveness in monitoring treatment response.
The randomized CAVE-2 GOIM trial demonstrates that while adding avelumab to cetuximab rechallenge does not improve survival in metastatic colorectal cancer, liquid biopsy-based genomic hyper-selection identifies a subgroup of patients with
This review synthesizes recent evidence (2021–2025) on circulating tumor DNA-guided adjuvant therapy, highlighting advances in personalized cancer management and emerging challenges.
